Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Uveal Melanoma Therapeutic Pipeline Market Review, H2 2016

Thursday, October 20, 2016 22:20
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Uveal Melanoma – Pipeline Review, H2 2016’, provides an overview of the Uveal Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @


- The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma
- The report reviews pipeline therapeutics for Uveal Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Uveal Melanoma therapeutics and enlists all their major and minor projects
- The report assesses Uveal Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Uveal Melanoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Uveal Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Complete report details @


Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Report Coverage 8
Uveal Melanoma Overview 9
Therapeutics Development 10
Pipeline Products for Uveal Melanoma – Overview 10
Pipeline Products for Uveal Melanoma – Comparative Analysis 11
Uveal Melanoma – Therapeutics under Development by Companies 12
Uveal Melanoma – Therapeutics under Investigation by Universities/Institutes 13
Uveal Melanoma – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Uveal Melanoma – Products under Development by Companies 17
Uveal Melanoma – Products under Investigation by Universities/Institutes 18
Uveal Melanoma – Companies Involved in Therapeutics Development 19
Aura Biosciences, Inc. 19
Bellicum Pharmaceuticals, Inc. 20
Celldex Therapeutics, Inc. 21
Cleveland BioLabs, Inc. 22
Eli Lilly and Company 23
Iconic Therapeutics, Inc. 24
Immunocore Limited 25
Navigen Pharmaceuticals, Inc. 26
Novartis AG 27
PEP-Therapy SAS 28
Pfizer Inc. 29
Spectrum Pharmaceuticals, Inc. 30
Uveal Melanoma – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 35
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
alpelisib – Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
AU-011 – Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
BPX-701 – Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma – Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
crizotinib – Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
DPTC-9h – Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
emibetuzumab – Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
entolimod – Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
glembatumumab vedotin – Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
hI-con1 – Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
HPH-196 – Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
HPH-211 – Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
IMCgp-100 – Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
KCN-1 – Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
LXS-196 – Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
merestinib – Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
NAV-2729 – Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
nutlin-3 – Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
pasireotide ER – Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
sotrastaurin acetate – Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
sunitinib malate – Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Vaccine 2 for Melanoma – Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Vaccine for Oncology – Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
vincristine sulfate – Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Uveal Melanoma – Dormant Projects 100
Uveal Melanoma – Discontinued Products 101
Uveal Melanoma – Product Development Milestones 102
Featured News & Press Releases 102
Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016 102
Mar 30, 2016: Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma 102
Jan 25, 2016: Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma 103
Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC 103
Sep 09, 2015: Immunocore’s IMCgp100 Accepted for Adaptive Pathway Pilot Programme 104
Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma 104
May 21, 2015: FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma 105
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108

Get It Now @


Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          


Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.